Lysosomal acid lipase, CSF1R and PD-L1 determine functions of CD11c+ myeloid-derived suppressor cells

Ting Zhao, …, Hong Du, Cong Yan


In-Press Preview

Graphical abstract

Find the latest version:

https://jci.me/156623/pdf
Lysosomal Acid Lipase, CSF1R and PD-L1 Determine Functions of CD11c⁺ Myeloid-Derived Suppressor Cells

Ting Zhao,¹ Sheng Liu,²,³ Xinchun Ding,¹ Erica M. Johnson,¹ Nasser H. Hanna,² Kanhaiya Singh,⁴ Chandan K Sen,⁴ Jun Wan,²,³ Hong Du,¹,² and Cong Yan ¹,²

¹Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
²IU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA
³Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA
⁴Indiana Center for Regenerative Medicine and Engineering, Indiana University School of Medicine, Indianapolis, Indiana, USA

The authors have declared that no conflict of interest exists.

Correspondence: Dr. Cong Yan, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 975 W Walnut Street, IB424G, Indianapolis, IN 46202. E-mail: coyan@iupui.edu. Tel: 1-317-278-6005; or Dr. Hong Du, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 975 W Walnut Street, IB424E, Indianapolis, IN 46202. E-mail: hongdu@iupui.edu. Tel: 1-317-274-6535.
Abstract

Lysosomal acid lipase (LAL) is a key enzyme in the metabolic pathway of neutral lipids. In the blood of LAL deficient (Lal−/−) mice, increased CD11c+ cells were accompanied by up-regulated PD-L1 expression. Single cell RNA sequencing of Lal−/− CD11c+ cells identified two distinctive clusters with a major metabolic shift towards glucose utilization and reactive oxygen species (ROS) over-production. Pharmacologically blocking pyruvate dehydrogenase in glycolysis not only reduced CD11c+ cells and their PD-L1 expression, but also reversed their capabilities of T cell suppression and tumor growth stimulation. Colony-stimulating factor 1 receptor (CSF1R) plays an essential role in controlling Lal−/− CD11c+ cell homeostasis and function and PD-L1 expression. Inhibition of LAL activity by pharmacological inhibitor increased CD11c, PD-L1 and CSF1R levels in both normal murine myeloid cells and human blood cells. Tumor-bearing mice and human non-small-cell lung cancer (NSCLC) patients also showed CD11c+ cell expansion with PD-L1 and CSF1R up-regulation and immunosuppression. There were positive correlations among CD11c, PD-L1 and CSF1R expression and negative correlations with LAL expression in lung cancer and melanoma patients using the TCGA database and patient samples. Therefore, CD11c+ cells switched their functions to immune suppression and tumor growth stimulation through CSF1R/PD-L1 upregulation and metabolic reprogramming.

Keywords: CD11c+ cells, lysosomal acid lipase, single cell RNA sequencing, metabolic reprogramming, CSF1R, PD-L1, lung cancer, melanoma
Introduction

Immune cells in the tumor microenvironment actively participate in cancer initiation, progression and metastasis (1). Thus, interactions between immune cells and tumor cells determine the balance between immunity and tolerance to tumor cells. The signaling pathway of programmed death-ligand 1 (PD-L1, B7-H1 or CD274) and its receptor PD-1 (CD279) is an important mechanism utilized by tumors to escape antitumor immune responses (2, 3), and maintain an immunosuppressive state in the tumor environment (4). PD-L1 binds to PD-1 or CD80 (B7-1) on activated T cells to mediate an inhibitory signal, and to prevent the immune system from rejecting the tumor (5, 6). Antibody-based therapeutics targeting PD-L1 have shown clinical responses in multiple tumor types (7, 8). PD-L1 is broadly expressed in hematopoietic cells, including dendritic cells (DCs) (9). Blockade of PD-L1 on DCs has been reported to enhance T cell activation and cytokine production (10). However, it is still not entirely clear how PD-L1 expression is regulated in immune cells to affect tumor progression. DCs are a diverse group of specialized antigen-presenting cells (APCs) with key roles in the initiation and regulation of innate and adaptive immune responses. Much interest in modulating DC function has been given to cancer immunotherapy by generations of DC-based vaccines (11-13). Most DCs express CD11c as a surface marker (12, 14). The diversity and functions of CD11c+ cell subsets that are shaped by pathogenic conditions are not completely understood, especially those CD11c+ cells that tolerate and stimulate cancer growth.

Lysosomal acid lipase (LAL) is a key enzyme in the metabolic pathway of neutral lipids, which hydrolyzes cholesteryl esters and triglycerides in the lysosome of cells to generate free fatty acids and cholesterol. Clinical case reports indicated that mutations
of the LAL gene were associated with carcinogenesis in patients (15). In LAL knockout (Lat⁻/⁻) mice, myeloid populations systemically expand from hematopoietic progenitors in the bone marrow, suppress T cell proliferation and function, and stimulate tumor growth and invasion in both syngeneic and allogeneic backgrounds (16-18). The LAL deficiency-induced immunocompromise also allows growth of human cancer cells in mice (19).

The present study found that LAL deficiency in the Lat⁻/⁻ mouse model increased the CD11c⁺ cell population in the blood that was associated with up-regulation of PD-L1 expression. These Lat⁻/⁻ CD11c⁺ cells shared characteristics of myeloid-derived suppressor cells (MDSCs) by suppressing T cells and stimulating tumor growth. Single cell RNA sequencing (scRNA-seq) analysis identified two distinct clusters with differential gene expression patterns, and revealed a major metabolic shift towards glucose utilization and reactive oxygen species (ROS) over-production in Lat⁻/⁻ CD11c⁺ cells. Colony-stimulating factor 1 receptor (CSF1R) has been identified as a gateway keeper in controlling Lat⁻/⁻ CD11c⁺ cell homeostasis and functions. Findings discovered in CD11c⁺ cells of Lat⁻/⁻ mice were also reproduced in CD11c⁺ cells of tumor-bearing mice and human cancer patients. In humans, there were positive correlations among CD11C, CD274 (PD-L1), CSF1R and IFNG (IFNγ) expression and negative correlations with LIPA (LAL) expression in multiple cancer forms using The Cancer Genome Atlas (TCGA) database. Human non-small-cell lung cancer (NSCLC) patients showed CD11c⁺ cell expansion with PD-L1 and CSF1R up-regulation and decreased LAL expression in their blood. These studies demonstrate that in addition to their APC function, CD11c⁺ cells are able to switch to subpopulations that exhibit immune suppression and tumor growth stimulation in the
tumor environment as a result of metabolic reprogramming, and PD-L1 and CSF1R up-regulation.
Results

Increase of PD-L1 expression in $Lal^{-/-}$ CD11c$^+$ cells.

The percentage of PD-L1$^+$ cells in the whole blood was increased in $Lal^{-/-}$ mice vs. $Lal^{+/+}$ mice (Figure 1A and Supplemental Figure 1A). Since T cells in the blood of $Lal^{-/-}$ mice were dramatically reduced compared with those of $Lal^{+/+}$ mice (20), it is unlikely that the T cells are responsible for the increase of PD-L1 expression. To further assess which cell population in the myeloid component is responsible for the increase of PD-L1 expression, the PD-L1 level in various myeloid cell subtypes was analyzed by flow cytometry. Compared with $Lal^{+/+}$ mice, PD-L1 expression was up-regulated in CD11c$^+$, MHC$^+$, F4/80$^+$, CD11b$^+$, Ly6C$^+$, and Ly6G$^+$ myeloid cells from the blood of $Lal^{-/-}$ mice when a single surface marker was used (Figure 1B). However, further analyses demonstrated that all the CD11c$^-$ double gated myeloid subtypes, including CD11b$^+$CD11c$^-$, MHC$^+$CD11c$^-$, F4/80$^+$CD11c$^-$, Ly6C$^+$CD11c$^-$, and Ly6G$^+$CD11c$^-$ cells, showed no increase in PD-L1 expression, while all the CD11c$^+$ double gated myeloid subtypes, including CD11b$^+$CD11c$^+$, MHC$^+$CD11c$^+$, F4/80$^+$CD11c$^+$, Ly6C$^+$CD11c$^+$, and Ly6G$^+$CD11c$^+$ cells, showed increased PD-L1 expression in the blood of $Lal^{-/-}$ mice vs. $Lal^{+/+}$ mice (Figure 1C). An example of PD-L1 expression in CD11b$^+$CD11c$^-$ and CD11b$^+$CD11c$^+$ cells and their gating strategy are shown in Supplemental Figure 1B.

This concludes that LAL deficiency-induced PD-L1 expression was restricted to the CD11c$^+$ myeloid subpopulation, whose percentage was increased in the blood of $Lal^{-/-}$ mice vs. $Lal^{+/+}$ mice (Figure 1D and Supplemental Figure 1C). Flow cytometry analysis also showed up-regulation of MFI of IFN$\gamma$, MCP-1, GM-CSF and IL-10 proteins in $Lal^{-/-}$ CD11c$^+$ cells vs. $Lal^{+/+}$ CD11c$^+$ cells (Figure 1E). The percentage differences are shown
in Supplemental Figure 1D-E, in which IFNγ, MCP-1, GM-CSF, IL-10, IL-1β and IL-2 showed statistically significant differences. IFNγ has been reported to regulate PD-L1 expression (21). To see whether IFNγ produced by CD11c+ cells is essential for PD-L1 expression, Lal+/+ or Lal-/- CD11c+ cells were treated with IFNγ neutralizing antibody or control IgG for 2 days. The percentage of PD-L1+ cells was decreased in CD11c+ cells with IFNγ neutralizing antibody treatment (Supplemental Figure 1F), suggesting that CD11c+ cells-derived IFNγ participates in regulating PD-L1 expression.

Lal-/- CD11c+ cells suppress T cell proliferation and stimulate tumor growth through PD-L1.

The functions of Lal-/- CD11c+ cells are characterized. First, freshly isolated Lal+/+ or Lal-/- CD11c+ blood cells were co-cultured with wild type splenic CD4+ T cells for CFSE proliferation assay in vitro, in which Lal-/- CD11c+ cells drastically suppressed CD4+ T cell proliferation vs. Lal+/+ CD11c+ cells (Figure 2A). The in vivo ratios of CD4+ T cells:CD11c+ cells and CD8+ T cells:CD11c+ cells were also greatly decreased in the blood of Lal-/- mice (Figure 2B). To evaluate if the up-regulated PD-L1 expression in Lal-/- CD11c+ cells is responsible for the suppression of T cell proliferation, CFSE-labeled T cells were co-cultured with isolated Lal+/+ or Lal-/- CD11c+ cells that were pre-treated with control IgG or anti-PD-L1 antibody. Results showed that blocking PD-L1 with anti-PD-L1 antibody reversed the Lal-/- CD11c+ cells’ suppressive activity on T cell proliferation (Figure 2C).

Next, isolated Lal+/+ or Lal-/- CD11c+ cells were subcutaneously co-injected with B16 melanoma cells into Lal+/+ recipient mice at flank sites. Compared with Lal+/+ CD11c+ cells, Lal-/- CD11c+ cells stimulated tumor growth in vivo (Figure 2D). However, after pre-
treated with anti-PD-L1 antibody, \( \text{Lai}^-/^- \) CD11c$^+$ cells’ stimulation of tumor growth was reversed (Figure 2E).

Characteristics of \( \text{Lai}^-/^- \) vs. \( \text{Lai}^{+/+} \) CD11c$^+$ cells by scRNA-seq.

Since \( \text{Lai}^-/^- \) CD11c$^+$ cells showed opposite effects (e.g., T cell suppression and tumor stimulation) of normal DCs (e.g., T cell stimulation and tumor suppression), it is important to reveal the intrinsic molecular transition and get a more comprehensive understanding between \( \text{Lai}^-/^- \) and \( \text{Lai}^{+/+} \) CD11c$^+$ cells. scRNA-seq is a powerful technique to clarify heterogeneity of the immune system by identifying novel distinct immune cell subsets and building trajectories for immune cells (22). CD11c$^+$ cells were isolated from the blood of \( \text{Lai}^{+/+} \) and \( \text{Lai}^-/^- \) mice for scRNA-seq analysis. T-stochastic neighbor embedding (tSNE) plot analysis identified two major distinctive cellular clusters of CD11c$^+$ cells: 1) clusters 1, 5, 8 (referred to as cluster 158 hereafter) with increased cellular numbers in \( \text{Lai}^-/^- \) CD11c$^+$ cells vs. \( \text{Lai}^{+/+} \) CD11c$^+$ cells, and 2) clusters 0, 2, 3, 6 (referred to as cluster 0236 hereafter) with decreased cellular numbers in \( \text{Lai}^-/^- \) CD11c$^+$ cells vs. \( \text{Lai}^{+/+} \) CD11c$^+$ cells (Figure 3A). Cluster 158 demonstrated the monocyte feature, while cluster 0236 demonstrated the neutrophil feature (Supplemental Table 1). Interestingly, there were significantly more \( \text{Cd274} \) (gene name of PD-L1) positive cells in cluster 158, and less in cluster 0236 of \( \text{Lai}^-/^- \) vs. \( \text{Lai}^{+/+} \) CD11c$^+$ cells (Figure 3B). There were more \( \text{Adgre1, Ly6c1, Ly6g, Ifng, Ccl2, Csf2 and Iil10} \) (gene names of F4/80, Ly6C, Ly6G, IFNγ, MCP-1, GM-CSF and IL-10, respectively) positive cell in cluster 158 of \( \text{Lai}^-/^- \) vs. \( \text{Lai}^{+/+} \) CD11c$^+$ cells (Supplemental Figure 2). Other top 50 up-regulated and down-regulated genes in cluster158 and cluster 0236 of \( \text{Lai}^-/^- \) CD11c$^+$ cells can be categorized into three groups,
1) cellular numbers increased in cluster 158 and relatively no change in cluster 0236 (Figure 3C); 2) cellular numbers increased in cluster 158 and decreased in cluster 0236 (Figure 3D); 3) cellular numbers increased in cluster 0236 and no change or increased in cluster 158 (Figure 3E). Log FC, gene expression, and cellular numbers of the top 50 up-regulated and down-regulated genes among all clusters, cluster 158, and cluster 0236 are presented in Supplemental Table 2-7, respectively.

**Metabolic reprogramming in Lat−/− CD11c+ cells.**

Metabolic regulation is important to myeloid differentiation and function (23-27). LAL deficiency reduces fatty acid oxidation, which leads to metabolic reprogramming of Lat−/− CD11c+ cells. Veritably, tSNE plots and pathway analysis of scRNA-seq showed that genes involved in glycolysis and the citrate cycle were up-regulated in Lat−/− vs. Lat+/+ cluster 158 of CD11c+ cells (Figure 4A-B and Supplemental Figure 3A-C), which overlap with the increased Cd274 expression in tSNE plots (Figure 3B). This metabolic reprogramming was associated with ROS over-production (Figure 4C and Supplemental Figure 3D). When expression of genes responding to ROS (selected from the MGI database) was compared between these two clusters, there was a significant shift from cluster 0236 to cluster 158 (Figure 4D). This observation was confirmed by trajectory analysis (Supplemental Figure 3E), in which trajectory dynamic changes and differential lineages were clearly different in cluster 158 and cluster 0236 of Lat−/− vs. Lat+/+ CD11c+ cells. Accordingly, scRNA-seq analysis showed up-regulation of Gsr gene (encoding for glutathione reductase, an important cellular antioxidant enzyme) in both cluster 158 and cluster 0236 of Lat−/− CD11c+ cells (Figure 3E and Supplemental Figure 3F). Seahorse
studies showed that both glycolytic metabolism and oxidative phosphorylation (OXPHOS) in mitochondrial respiration were significantly increased in Lal−/− vs. Lal+/+ CD11c+ cells by extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) analyses (Figure 4E and Supplemental Figure 4A-B). In addition, Lal−/− CD11c+ cells demonstrated a higher rate of ATP production than that of Lal+/+ CD11c+ cells (Figure 4F). Protein expression of several key metabolic enzymes in glucose metabolism, including pyruvate dehydrogenase (PDH), glucose-6-phosphate dehydrogenase (G6PD), and lactate dehydrogenase (LDH), were all significantly increased in Lal−/− CD11c+ cells compared to those in Lal+/+ CD11c+ cells (Figure 4G and Supplemental Figure 4C-D). Additionally, glutamate dehydrogenase (GLUD) in the glutamine pathway showed up-regulation in Lal−/− CD11c+ cells at the protein level (Figure 4G and Supplemental Figure 4C-D). These results suggest a metabolic switch to glucose and amino acid utilization in Lal−/− CD11c+ cells.

Interestingly, PD-L1 expression was subjective to metabolic switch regulation, as injection of PDH inhibitor CPI-613 into Lal−/− mice reduced the CD11c+ cell population, and PD-L1 expression in Lal−/− CD11c+ cells (Figure 4H). Furthermore, CPI-613 pre-treated Lal−/− CD11c+ cells showed reduced capabilities in T cell suppression when co-cultured with CD4+ T cells in vitro (Figure 4I) and tumor growth stimulation when co-injected with B16 melanoma cells subcutaneously in Lal+/+ mice (Figure 4J). Clearly, blocking PDH in the glycolysis pathway impaired Lal−/− CD11c+ cells’ immunosuppressive and tumor stimulatory functions. However, CPI-613 treatment in Lal−/− CD11c+ cells did not change the IFNγ expression level (Supplemental Figure 4E).
CSF1R controls *Lat⁻/⁻* CD11c⁺ cells’ PD-L1 regulation, T cell suppression and tumor growth stimulation.

In searching for molecular signaling that controls PD-L1 up-regulation in *Lat⁻/⁻* CD11c⁺ cells, CSF1R was selected based on scRNA-seq analysis (Figure 3C), as it plays a critical role in myeloid genesis and promotes the differentiation of progenitors into heterogeneous populations of myeloid cells (28, 29). Importantly, tSNE plot analysis of CD11c⁺ cells showed that the number of *Csf1r* gene positive cells was increased in cluster 158 of *Lat⁻/⁻* CD11c⁺ blood cells (Figure 3C and 5A), which overlaps with the increased *Cd274* expression (Figure 3B) and the metabolic switch (Figure 4A-B). Flow cytometry analysis confirmed the increased level of CSF1R protein in the *Lat⁻/⁻* CD11c⁺ blood cells (Figure 5B and Supplemental Figure 5A). However, this was not the case in *Lat⁻/⁻* CD11b⁺Ly6G⁺ cells (Supplemental Figure 5B), a traditional *Lat⁻/⁻* MDSC population that also strongly suppresses T cell proliferation (16, 18, 30) and stimulates tumor growth (17). CSF1R expression was up-regulated in CD11c⁺ myeloid cells from *Lat⁻/⁻* mice, including CD11b⁺CD11c⁺, Ly6C⁺CD11c⁺, Ly6G⁺CD11c⁺, MHCII⁺CD11c⁺, and F4/80⁺CD11c⁺ cells (Supplemental Figure 5C). To evaluate if the up-regulated CSF1R expression in *Lat⁻/⁻* CD11c⁺ cells is responsible for *Lat⁻/⁻* CD11c⁺ cell immunosuppressive and tumor stimulatory functions, isolated *Lat⁺/+* or *Lat⁻/⁻* CD11c⁺ cells were pre-treated with control IgG or anti-CSF1R antibody, and then co-cultured with splenic CD4⁺ T cells in vitro or subcutaneously co-injected with B16 melanoma cells in vivo. Results showed that blocking CSF1R reversed *Lat⁻/⁻* CD11c⁺ cells’ suppressive activity on T cell proliferation (Figure 5C) and impaired stimulation of tumor growth in mice (Figure 5D). Furthermore, treatment of *Lat⁻/⁻* mice with anti-CSF1R antibody decreased the percentage and MFI of
PD-L1$^+$ cells in CD11c$^+$ blood cells (Figure 5E and Supplemental Figure 5D), suggesting that the PD-L1 level was regulated by CSF1R. In the T cell suppression study, the source of CSF1R ligand CSF1 came from both CD11c$^+$ and CD4$^+$ T cells. *Lal$^{-/-}$* CD11c$^+$ cells showed higher CSF1 production than *Lal$^{+/+}$* CD11c$^+$ cells, while CD4$^+$ T cells showed lower production of CSF1 (Supplemental Figure 5E). However, the IFNγ level was not significantly changed by blocking CSF1R in *Lal$^{-/-}$* CD11c$^+$ cells (Supplemental Figure 5D). A doxycycline-inducible hLAL myeloid-specific expressing c-fms-Tg/KO triple mouse model (18) was used to test if human LAL expression in myeloid cells corrects CSF1R and PD-L1 up-regulation in CD11c$^+$ cells. Indeed, compared to doxycycline-untreated c-fms-Tg/KO triple mice (-DOX group), myeloid-specific expression of hLAL (+DOX group) corrected the increased percentages and MFI of CSF1R$^+$, PD-L1$^+$, IFNγ$^+$ and PD-L1$^+$CSF1R$^+$ double positive populations in *Lal$^{-/-}$* CD11c$^+$ cells, and decreased the percentage of CD11c$^+$ cell population (Figure 5F and Supplemental Figure 5F). Therefore, myeloid expression of human LAL in the humanized model critically controls *Lal$^{-/-}$* CD11c$^+$ cell homeostasis and pathogenic functions through the CSF1R/PD-L1 axis.

**Pharmacological inhibition of LAL up-regulates the expression of CD11c, PD-L1 and CSF1R in murine HD1A myeloid cells and human blood cells.**

The above observations were based on the genetic loss of LAL in mice. To confirm these findings by pharmacological inhibition, a LAL-specific inhibitor Lalistat2 (31, 32) was used to treat murine HD1A myeloid cell line that was established previously (33). The LAL enzymatic activity in HD1A myeloid cells was inhibited by Lalistat2 in a dose-dependent fashion (Figure 6A). As Figure 6B and Supplemental Figure 6A shown,
Lalistat2 treatment significantly increased the percentages of CD11c+, PD-L1+ and CSF1R+ cells in a concentration-dependent fashion in HD1A cells. Western blot analysis further confirmed the up-regulation of PD-L1 in HD1A cells after Lalistat2 treatment (Figure 6C).

To replicate mouse observations in humans, the human blood was collected from healthy subjects and treated with Lalistat2. The expression levels of PD-L1 and CSF1R in CD11c+ cells were gated and analyzed by flow cytometry. As demonstrated in Figure 6D-E and Supplemental Figure 6B, Lalistat2 treatment significantly increased the percentages of CD11c+ cells in the human blood, and the percentages of PD-L1+ cells and CSF1R+ cells in human blood CD11c+ cells.

Expression of PD-L1, CSF1R and metabolic enzymes in immunosuppressive CD11c+ cells of tumor-bearing mice and cancer patients.

The Lal−/− mouse model has a pre-existing condition in favor of tumor growth. To extend the above findings to tumor-induced models (post-tumor injection), B16 melanoma or LLC cells were subcutaneously injected into the flank sites of Lal+/+ recipient mice in both syngeneic C57BL/6 and allogeneic FVB/N genetic backgrounds for 14 days. The blood was collected from these mice for flow cytometry analysis. As demonstrated in Figure 7A, percentages of CD11c+ cells in the blood were increased in tumor-bearing mice, including B16-injected FVB/N and C57BL/6 mice, and LLC-injected FVB/N and C57BL/6 mice. Both the MFI and percentages of PD-L1+ cells in CD11c+ cells were up-regulated in the blood of these tumor-bearing mice (Figure 7B and Supplemental Figure 7A-B). Both the MFI and percentages of CSF1R were increased in CD11c+ cells of B16-
injected vs. those of PBS-injected FVB/N mice as well (Figure 7C and Supplemental Figure 7A and 7C). MFI and percentages of metabolic enzyme PDH were significantly increased in CD11c+ cells of B16-injected vs. those of PBS-injected FVB/N mice (Figure 7D and Supplemental Figure 7A and 7D). When co-cultured with CD4+ T splenic cells, CD11c+ cells isolated from the blood of B16-injected mice suppressed T cell proliferation (Figure 7E), demonstrating that they had immunosuppressive functions similar to *Lal*-/- CD11c+ cells. Taken together, tumor-induced mice (post-tumor model) shared characteristics of *Lal*-/- mice (pre-tumor model) by increasing CD11c+ cells with immunosuppressive activity in the blood, in which PD-L1, CSF1R, and glucose metabolic enzyme were upregulated. In addition to these peripheral CD11c+ cells in tumor-bearing mice, Supplemental Figure 7E and 7F showed that the percentages of CD11c+ cells were increased in tumor tissues, accompanied with up-regulated PD-L1 expression. However, the percentages of CSF1R+ cells in these CD11c+ cells were decreased. In *Lal*-/- mice, no increased CD11c+ cells were observed in tumor tissues (Supplemental Figure 7G), probably due to pool exhaustion as the myeloid compartment is already expanded in these mice. In addition, increased PD-L1 expression and decreased CSF1R level were observed in CD11c+ cells of tumor tissues from *Lal*-/- mice (Supplemental Figure 7H).

To explore whether expressions of PD-L1, CSF1R and IFNγ are correlated with CD11c expression in human cancer patients, data mining analyses were performed in human Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC) and Skin Cutaneous Melanoma (SKCM) samples of the TCGA database. Results showed that there were positive correlations between *CD11C* expression vs. *CD274* expression, *CD11c* expression vs. *CSF1R* expression, *CSF1R* expression vs. *CD274* expression,
IFNG expression vs. CD11c expression, IFNG expression vs. CD274 expression, and IFNG expression vs. CSF1R expression in lung cancer and melanoma patients (Figure 7F-H). To confirm these observations, the blood was collected from healthy controls and NSCLC patients with PD-L1 positive scores, and stained with fluorescence-conjugated antibodies for flow cytometry analysis. As Figure 7I demonstrated, the percentages of CD11c+ cells, PD-L1+ cells, and CSF1R+ cells were all increased in the whole blood of NSCLC patients compared to healthy controls. There were more PD-L1+ and CSF1R+ cell populations in gated CD11c+ cells of NSCLC patients than those of healthy controls (Figure 7J and Supplemental Figure 7I). In contrast, within CD11b+HLA-DR- myeloid cells, there was relatively no change in percentages of PD-L1+ cells or CSF1R+ cells (Supplemental Figure 7I-J). MFI and percentages of metabolic enzyme PDH were significantly increased in CD11c+ cells of NSCLC patients compared to healthy controls (Figure 7K and Supplemental Figure 7K).

Interestingly, data mining analyses of the TCGA database revealed down-regulation of LAL gene expression in various human cancer forms, including Breast Cancer (BRCA), Kidney Chromophobe (KICH), LUAD, LUSC, Pancreatic adenocarcinoma (PAAD), SKCM and Uterine Corpus Endometrial Carcinoma (UCEC) (Figure 7L). LAL levels were further examined in blood CD11c+, PD-L1+, and CSF1R+ cells of NSCLC patients by flow cytometry analysis. Importantly, Figure 7M and Supplemental Figure 7L showed that the LAL levels were decreased not only in the whole blood cells, but also in CD11c+, PD-L1+, and CSF1R+ cells of NSCLC patients compared to healthy controls. Therefore, there is a negative correlation between LAL expression
and expansion of CD11c⁺, PD-L1⁺, and CSF1R⁺ cells in NSCLC patients, similar to that observed in the *Lal*⁻/⁻ model and tumor-bearing mice.
Discussion

Anti-tumor immune suppression is a complicated process, which involves both T cell and myeloid cell components in the ecosystem of tumor microenvironment. Among all immune therapies, the PD-L1/PD-1 checkpoint pathway has so far been proven to be a valuable therapeutic target to eradicate malignancies. Engagement of PD-1 by PD-L1 alters the activity of T cells in many ways, including inhibiting T cell proliferation, survival, cytokine production, and other effector functions. In our study, PD-L1 is subjective to neutral lipid regulation that is controlled by LAL. In \textit{Lal}^{-/-} mice, increased PD-L1 expression was observed in whole blood (Figure 1A). Since the \textit{Lal}^{-/-} mouse model provides a favorable environment for tumor growth and metastasis (17), it is intriguing to determine if PD-L1 plays a role in this environment and reveal which immune components contribute to the increase of PD-L1 expression. It is unlikely that increased PD-L1 expression came from the T cell component because \textit{Lal}^{-/-} mice have impaired development and proliferation of T cells (20), which results in extremely low levels of T cells in most immune organs. In contrast, \textit{Lal}^{-/-} mice have robust proliferation of myeloid cells that is initiated in the early stages of myelopoiesis in the bone marrow (16, 18, 30). Therefore, the search for the increased PD-L1 expression was mainly focused on the myeloid lineage of \textit{Lal}^{-/-} mice.

Flow cytometry analysis using various myeloid surface markers revealed that PD-L1 expression was only up-regulated in CD11c$^+$ myeloid cells of \textit{Lal}^{-/-} mice (Figure 1B-C). Functionally, isolated \textit{Lal}^{-/-} CD11c$^+$ blood cells possessed strong T cell suppression and stimulation of tumor cells (Figure 2), which are two hallmarks of \textit{Lal}^{-/-} MDSCs (16-18). Based on these similarities and standards, \textit{Lal}^{-/-} CD11c$^+$ cells are referred to as CD11c$^+$

17
MDSCs in order to distinguish them from traditional CD11b⁺Ly6G⁺ MDSCs in \(\text{Lal}^{-/-}\) mice.

Unlike MDSCs from tumor-bearing mice that are divided into “monocytic” and “granulocytic” MDSCs (34-36), almost all traditional \(\text{Lal}^{-/-}\) MDSCs are Ly6G⁺Ly6C⁺ (18).

CD11c is typically considered to be a marker of conventional DCs (11-14), although it has been reported to be expressed on monocytes, granulocytes, macrophages, and a subset of B cells, T cells, and natural killer (NK) cells (37-41). It appears that CD11c⁺ cells are a highly plastic population with diverse functions in various disease models. These diverse populations were also observed in the \(\text{Lal}^{+/+}\) and \(\text{Lal}^{-/-}\) blood, although most CD11c⁺ cells possess either neutrophil (cluster 0236) or monocyte (cluster 158) features (Supplemental Table 1).

It is important to distinguish similarities and differences between \(\text{Lal}^{-/-}\) CD11b⁺Ly6G⁺ MDSCs and \(\text{Lal}^{-/-}\) CD11c⁺ MDSCs at the cellular and molecular levels. In fat catabolism, triglycerides are hydrolyzed to break into fatty acids and glycerol by LAL. Fatty acids are further broken down through the process of beta oxidation (FAO) that results in acetyl-CoA, which can be used in the tricarboxylic acid (TCA) cycle in mitochondria. In the absence of the regular supply of fatty acids during LAL deficiency, cells inevitably use substitutive energy consumption pathways to fuel oxidative phosphorylation (OXPHOS). In \(\text{Lal}^{-/-}\) CD11b⁺Ly6G⁺ MDSCs, Affymetrix GeneChip microarray and Ingenuity Pathway analyses identified the upregulation of many enzymes that are involved in the glycolytic pathway and the TCA cycle. In addition, gene expressions of lactate dehydrogenases, enzymes in the pentose phosphate pathway (energy conservation for biosynthetic purposes), and glycogen synthesis (storage form of glucose and metabolic energy) were up-regulated in \(\text{Lal}^{-/-}\) CD11b⁺Ly6G⁺ MDSCs (42).
the present study, by using Seahorse analysis for ECAR and OCR measurements, both glycolytic metabolism and OXPHOS in mitochondrial respiration were significantly increased in \( \textit{Lal}^{-/-} \) CD11c\(^+\) MDSCs, accompanied with higher ATP production (Figure 4E-F). scRNA-seq and tSNE clustering approaches showed that genes involved in glycolysis and the TCA cycle were up-regulated in \( \textit{Lal}^{-/-} \) CD11c\(^+\) MDSCs (Figure 4A-B and Supplemental Figure 3A-B). These observations were confirmed by flow cytometry analysis in which protein expression levels of several key glucose downstream metabolic enzymes (PDH, G6PD, LDH) and GLUD were increased in \( \textit{Lal}^{-/-} \) CD11c\(^+\) MDSCs (Figure 4G). During the process of glycolysis, glucose is broken down into pyruvate, which moves into the mitochondria. PDH plays a role in converting pyruvate into acetyl-CoA by decarboxylation to enter TCA cycle in mitochondria. G6PD and LDH control the pentose phosphate pathway and anaerobic glycolysis, respectively. GLUD participates in the glutamine pathway. Taken together, these results suggest a metabolic switch to overuse glucose and amino acids as the energy source in both \( \textit{Lal}^{-/-} \) CD11b\(^+\)Ly6G\(^+\) MDSCs and \( \textit{Lal}^{-/-} \) CD11c\(^+\) MDSCs. Importantly, inhibition of PDH by CPI-613 pharmacological inhibitor not only reduced the \( \textit{Lal}^{-/-} \) CD11c\(^+\) MDSCs population and their PD-L1 expression (Figure 4H), but also reversed their capabilities in T cell suppression and tumor growth stimulation (Figure 4I-J). Mitochondria help to control various metabolic decision points that determine immune cell functions (43). In \( \textit{Lal}^{-/-} \) CD11b\(^+\)Ly6G\(^+\) MDSCs, ROS were over-produced and accompanied by damaged mitochondrial function as a penalty of over-using glucose and amino acids (30). A similar observation was observed in \( \textit{Lal}^{-/-} \) CD11c\(^+\) MDSCs. There were major distinctions between gene expression patterns and trajectory lineage differentiation of the ROS pathway in cluster 158 and cluster 0236 of \( \textit{Lal}^{-/-} \) CD11c\(^+\)
MDSCs compared with $Lat^{+/+}$ CD11c$^+$ cells (Figure 4D and Supplemental Figure 3D-E), which was associated with high level ROS production (Figure 4C). The high level of ROS allows for the stimulation of cell proliferation, induction of genetic instability, and evasion from senescence (44). Accordingly, gene expression of glutathione reductase Gsr, a critical enzyme in redox regulation, was up-regulated in $Lat^{-/-}$ CD11c$^+$ MDSCs (Supplemental Figure 3F). Clearly, both $Lat^{-/-}$ CD11b$^+$Ly6G$^+$ MDSCs and $Lat^{-/-}$ CD11c$^+$ MDSCs share a specialized metabolism that differs from their normal counterparts. Metabolic switch and plasticity in the tumor environment compromise immune-mediated tumor destruction, and offer an opportunity to selectively target functions of immune cells for enhancing effective immunotherapy (25, 27).

However, there are significant differences between $Lat^{-/-}$ CD11b$^+$Ly6G$^+$ MDSCs and $Lat^{-/-}$ CD11c$^+$ MDSCs. At least two biomarkers (PD-L1, CSF1R) can be used to distinguish $Lat^{-/-}$ CD11b$^+$Ly6G$^+$ MDSCs and $Lat^{-/-}$ CD11c$^+$ MDSCs. First, increased PD-L1 expression was only observed in $Lat^{-/-}$ CD11c$^+$ MDSCs, not in $Lat^{-/-}$ CD11b$^+$Ly6G$^+$ MDSCs (Figure 1). Pre-treatment with anti-PD-L1 antibody reversed $Lat^{-/-}$ CD11c$^+$ MDSC suppressive activity of T cells (Figure 2C) and stimulation of tumor growth (Figure 2E). Blockade of PD-L1 on DCs has been reported to enhance T cell activation and cytokine production (10). In murine tumor infiltrating DCs, blockade of PD-L1 also resulted in a better capability to stimulate T cell activation, contributing to a more potent ability to inhibit tumor growth in mice (9, 45). Second, CSF1R expression was increased in cluster 158 of $Lat^{-/-}$ CD11c$^+$ MDSCs by scRNA-seq and flow cytometry analyses, but not in $Lat^{-/-}$ CD11b$^+$Ly6G$^+$ MDSCs (Figure 5A-B and Supplemental Figure 5B). Similar to PD-L1, pre-treatment with anti-CSF1R antibody reversed $Lat^{-/-}$ CD11c$^+$ MDSCs suppressive activity
on T cells (Figure 5C) and stimulation of tumor growth (Figure 5D). These observations in the genetically ablated system were confirmed in murine HD1A myeloid cell line by LAL pharmacological inhibitor Lalstat2 (Figure 6A-C). More importantly, Lalstat2 treatment induced PD-L1 and CSF1R expression in human blood CD11c⁺ myeloid cells (Figure 6D-E). Therefore, increased PD-L1 and CSF1R expression are the unique features of Lal⁻/⁻ CD11c⁺ MDSCs that can be used to distinguish them from Lal⁻/⁻ CD11b⁺Ly6G⁺ MDSCs. On the other hand, there was a report showing exclusive overexpression of fatty acid transport protein 2 (FATP2) that was controlled by granulocyte–macrophage colony-stimulating factor through the activation of the STAT5 transcription factor in PMN-MDSCs. Selective inhibition of FATP2 abrogated the activity of PMN-MDSCs and substantially delayed tumor progression (46).

In addition to the increased levels of PD-L1 and CSF1R, Lal⁻/⁻ CD11c⁺ MDSCs possess many other unique features. The scRNA-seq approach identified that CD11c⁺ MDSCs could be divided into two major cellular clusters in tSNE clustering analysis (cluster 158 and cluster 0236). Compared with Lal⁺/⁺ CD11c⁺ cells, Lal⁻/⁻ CD11c⁺ MDSCs showed increased cellular number in cluster 158 but decreased cellular number in cluster 0236 (Figure 3A). Considering that Lal⁻/⁻ CD11c⁺ MDSCs possessed immunosuppressive and tumor stimulatory functions instead of DCs’ traditional antigen-presenting immune stimulatory function, these two clusters may represent two sub-populations with distinctive functions. It has been reported that DCs switch from an immunostimulatory activation state driving anti-tumor immunity in early-stage tumors to an immunosuppressive activation state at later stages (47). The secretion of immunosuppressive factors by cancer cells has been proposed to be implicated in the
control of DC differentiation, maturation, and function (48). Similarly here, cluster 158 in 

$La^t$-CD11c$^+$ MDSCs may contribute to their immunosuppressive and tumor stimulatory functions. Indeed, the gene $Cd274$ (PD-L1) level was significantly increased in cluster 158, and slightly decreased in cluster 0236 of $La^t$-CD11c$^+$ MDSCs compared with $La^t/+ CD11c^+$ cells (Figure 3B). As demonstrated in Figure 2, $La^t$-CD11c$^+$ MDSCs exerted their immunosuppressive and tumor stimulatory functions by up-regulating PD-L1 expression. This was controlled by CSF1R, which has a similar gene expression pattern as PD-L1 in cluster 158 and cluster 0236 (Figure 5A). This CSF1R/PD-L1 axis in $La^t$-CD11c$^+$ MDSCs was at least, in part, responsible for $La^t$-CD11c$^+$ MDSCs' capabilities in suppressing T cells and stimulating tumor growth (Figure 5C-D). As demonstrated in Figure 3C-E and Supplemental Table 2-7, many other genes and pathways may also contribute to functional switch of CD11c$^+$ cells in the $La^t$-pro-tumor microenvironment. This opens a door for future investigation. For example, flow cytometry analysis showed up-regulation of IFNγ, MCP-1, GM-CSF and IL-10 proteins in $La^t$-CD11c$^+$ cells vs. $La^t/+ CD11c^+$ cells (Figure 1E). Among them, IFNγ has been reported to regulate PD-L1 expression (21). Indeed, the percentage of PD-L1$^+$ cells was decreased in $La^t$-CD11c$^+$ cells with IFNγ neutralizing antibody treatment (Supplemental Figure 1F). There were more $Ifng$ (gene name of IFNγ) positive cells in cluster 158 of $La^t$ vs. $La^t/+ CD11c^+$ cells (Supplemental Figure 2). Blocking CSF1R did not significantly change the IFNγ level in $La^t$-CD11c$^+$ cells (Supplemental Figure 5D), suggesting that PD-L1 is regulated by at least two independent pathways in these cells.

Although $La^t$ mice are a pre-tumor model, the findings observed in this model can be extended to tumor-bearing models. In both B16 melanoma and LLC tumor-bearing
mice, not only the percentages of CD11c+ cells in the blood were increased, but also expression of PD-L1, CSF1R, and PDH in CD11c+ cells were up-regulated (Figure 7A-D). Functionally, these CD11c+ cells from the B16 melanoma-induced model suppressed T cell proliferation (Figure 7E). Besides, the percentages of CD11c+ cells and the percentages of PD-L1+ cells in CD11c+ cells were also increased in the tumor tissues of these tumor-bearing mice (Supplemental Figure 7E-F). Thus, tumor-bearing mice shared similar characteristics of Lal−/− mice, and CD11c+ MDSC up-regulation is a common feature in both pre-tumor models (Lal−/−) and post-tumor (tumor-induced) models.

Importantly, when performing the correlation analyses in human cancer patients by data mining of the TCGA database, there were positive correlations among CD11C, CD274, CSF1R and IFNG expression in lung adenocarcinoma, lung squamous carcinoma and melanoma (Figure 7F-H). In addition, human NSCLC patients with PD-L1 positive scores confirmed the increased percentages of CD11c+ cells, and increased PD-L1, CSF1R and PDH expression in gated CD11c+ cells from blood (Figure 7I-K). In contrast, increase of PD-L1 or CSF1R expression was not observed in CD11b+HLA-DR− myeloid cells (representing PMN-MDSCs) (Supplemental Figure 7I-J), confirming that the increased expression of PD-L1 and CSF1R was only associated with CD11c+ cells, and less associated with “PMN-MDSCs” in NSCLC patients. Therefore, CD11c+ MDSC upregulation is common in the tumor environment of both tumor-bearing animal models and human cancer patients. This holds a great potential to design CD11c+ cell-based immunotherapy to enhance the efficacy of T cell-based checkpoint immunotherapy for cancer treatment. Recently, there was a report showing that PD-L1 was universally upregulated in tumor-derived LAMP3+ cDCs in almost all human cancer types (49).
Based on the present studies and previous publications, CD11c+ cells seem to possess dual functions depending on genetic defects and existing microenvironments, and can be divided into two subgroups: 1) an anti-tumor subgroup with APC/T cell stimulating/tumor suppressive functions, and 2) a pro-tumor subgroup with T cell suppressive/tumor stimulating functions. The LAL/CSF1R/PD-L1 axis is a major driver in the transition between these two subgroups through neutral lipid to glycolysis metabolic reprogramming.

Last but not least, LIPA expression was down-regulated in multiple forms of human cancers by data mining of the TCGA database (Figure 7L). Flow cytometry analysis further showed down-regulation of LAL in CD11c+, PD-L1+, and CSF1R+ cells of blood samples from NSCLC patients (Figure 7M). Therefore, observations made from both mouse models (Lal−/− and tumor-bearing) and human cancer patients support a notion that LAL plays a suppressive role in these oncogenic processes and can be used for the cancer immunotherapy purpose. LAL (commercial name Kanuma) can be used to treat cancer patients as immunotherapy to decrease pro-tumor immune cells in clinical settings. It is conceivable that LAL negatively promotes CSF1R and PD-L1 at the transcriptional level. LAL is well known for its role to activate nuclear receptors (e.g. PPARs) by generating hormone ligands. How CSF1R and PD-L1 genes are down-regulated by nuclear receptors at the transcriptional level warrants further investigation in the future. It is noticed that several Fos/Jun subunits of AP-1 transcription factor were co-upregulated in cluster 158, but down-regulated in cluster 0236 (Figure 3D). It is intriguing to see the connections between them and regulation of CSF1R and PD-L1 genes as well.
Methods

Animals and cell lines

Wild type (Lal+/+) and Lal−/− mice of the FVB/N and C57BL/6 background were bred inhouse (50, 51). Humanized c-fms-rtTA/(TetO)7-CMV-hLAL (c-fms-Tg/KO) mice of the FVB/N background are a previously generated triple transgenic mouse model with myeloid-specific doxycycline-inducible expression of wild-type human LAL (hLAL) in Lal−/− mice under the control of the c-fms promoter (18, 52). Both male and female mice aged three- to four-month-old were used, and all the mice have been backcrossed for more than 10 generations.

The murine B16 melanoma cell line and Lewis lung carcinoma (LLC) cell line (ATCC, Manassas, VA) were cultured in DMEM supplemented with 10% FBS (Gibco) in a 37°C incubator with 5% CO₂. The HD1A myeloid cell line were previously established in our lab (33) and cultured in RPMI 1640 supplemented with 10% FBS in a 33°C incubator with 8% CO₂. To inhibit the LAL activity, HD1A cells were treated with 10 µM, 50 µM, 100 µM or 200 µM LAL inhibitor Lalstat2 (Cayman, Ann Arbor, MI) for 72 h (31, 32). As a control, HD1A cells were treated with DMSO.

Human blood samples

The human blood samples of normal subjects were obtained from Indiana Biobank, and non-small-cell lung cancer (NSCLC at stage III-IV) patients were obtained from Simon Cancer Center Clinic of Indiana University School of Medicine after signing the consent form. NSCLC patients were selected by screening with PD-L1 Tumor Proportion Score (TPS) ≥ 10%. Both normal subjects and NSCLC patients include male and female,
White and African American. To inhibit the LAL activity, human blood cells from normal subjects were removed of red blood cells (RBCs) with lysis buffer (Biolegend, San Diego, CA) and washed with PBS by centrifugation at 240 x g for 5 min at room temperature, and then incubated with 10 µM LAL inhibitor Lalstat2 for 24 h. As a control, human blood cells were incubated with DMSO.

**Flow cytometry analysis**

$Lal^{+/+}$ and $Lal^{-/-}$ mice were euthanized, and the blood was immediately collected from the posterior vena cava. The blood was then treated with RBC lysis buffer to remove RBCs and washed with PBS. For analysis of PD-L1 and CSF1R expression in immune cell subtypes, cells were stained with APC-conjugated anti-CSF1R antibody (AFS98, cat#17-1152-82), APC eFluor 780-conjugated anti-Ly6G antibody (1A8-Ly6g, cat#47-9668-82), and APC eFluor 780-conjugated anti-F4/80 antibody (BM8, cat#47-4801-82), FITC-conjugated anti-CD11b antibody (M1/70, cat#11-0112-82), FITC-conjugated anti-MHCl antibody (M5/114.15.2, cat#11-5321-82), PE-conjugated anti-CD11c antibody (N418, cat#12-0114-82) (eBioscience, San Diego, CA), FITC-conjugated anti-Ly6C antibody (HK1.4, cat#128006), PE-Cy7-conjugated anti-PD-L1 antibody (10F.9G2, cat#124314) (Biolegend) at 4°C for 15 min. Cells were washed with PBS, then were ready for flow cytometry analysis.

For analyses of cytokine and metabolic enzyme levels in CD11c$^+$ cells, isolated cells were first stained with PE-conjugated or APC-conjugated (N418, cat#17-0114-82) anti-CD11c antibody at 4°C for 15 min. After being fixed and permeabilized using BD Cytofix/Cytoperme Fixation/Permeabilization Kit (BD Biosciences, San Jose, CA), cells
were incubated with fluorescence conjugated antibodies against intracellular molecules including APC-conjugated anti-IFNγ antibody (XMG1.2, cat#17-7311-82), APC-conjugated anti-IL-2 antibody (JES6-5H4, cat#17-7021-82), APC-conjugated anti-IL-10 antibody (JES5-16E3, cat#17-7101-82), FITC-conjugated anti-GM-CSF antibody (MP1-22E9, cat#17-7331-82), FITC-conjugated anti-IL-1β antibody (NJTEN3, cat#17-7114-80), PE-conjugated anti-MCP-1 antibody (2H5, cat#12-7096-82) (eBioscience), and non-fluorescence conjugated antibodies against metabolic molecules including glucose-6-phosphate dehydrogenase (G6PD) (D5D2, cat#12263S), lactate dehydrogenase (LDH) (C28H7, cat#3558S), pyruvate dehydrogenase (PDH) (cat#2784S), and glutamate dehydrogenase (GLUD) (D9F7P, cat# 12793S) (Cell Signaling, Beverly, MA) at 4°C overnight. On the next day, for non-fluorescence conjugated antibodies, cells were washed and stained with Alexa Fluor 647-conjugated anti-rabbit IgG antibody (cat#4414S) (Cell Signaling) at 4°C for 30 min, then washed for flow cytometry analysis.

For flow cytometry analysis of human blood samples, the human blood was removed of RBCs and washed with PBS, and then stained with APC-conjugated anti-CSF1R antibody, APC-eFluor 780-conjugated anti-CD11c antibody (3.9, cat#47-0116-42), PE-conjugated anti-PD-L1 antibody (MIH1, cat#12-5983-42), PE-Cy5-conjugated anti-CD11b antibody (ICRF44, cat#15-0118-42), PE-Cy7-conjugated anti-HLA-DR antibody (L243, cat#25-9952-42) (eBioscience) at 4°C for 15 min. Cells were then washed with PBS, fixed with 1% PFA, and ready for flow cytometry analysis. To analyze LAL levels, cells were further fixed and permeabilized using BD Cytofix/Cytoperm Fixation/Permeabilization Kit, and incubated with non-fluorescence conjugated anti-LAL antibody (53) , at 4°C overnight. On the next day, cells were washed and stained with
FITC-conjugated anti-rabbit IgG antibody at 4°C for 30 min, then washed for flow cytometry analysis.

For flow cytometry analysis, ≥50,000 cells were acquired and scored using a LSR II machine (mouse samples) or Fortessa (human samples) (BD Biosciences) and calculated based on isotype control. Data were processed using the BD CellQuest Pro software (version 19.f3fcf) and FlowJo (version 10.6.1) (BD Biosciences).

**Isolation of blood CD11c^+ cells**

The blood was collected from the posterior vena cava of mice. After removal of RBCs and PBS wash, cells were first incubated with biotin-conjugated anti-CD11c antibody (N418, cat#130-125-219) (Miltenyi Biotec., Auburn, CA) at 4°C for 30 min. After wash with PBS, cells were then incubated with anti-biotin microbeads at 4°C for another 30 min. Subsequently, cells were subjected to magnetic bead sorting according to the manufacturer’s instructions (Miltenyi Biotec.). For blocking antibody treatment, freshly isolated CD11c^+ cells were pre-treated with IgG or anti-PD-L1 (5 µg/mL) (10F.9G2, cat#124302, Biolegend) or anti-CSF1R antibodies (5 µg/mL) (AFS98, cat#14-1152-82, eBioscience) or anti-IFNγ (5 µg/mL) (37895, cat#MAB485-100, R&D Systems, Minneapolis, MN) at 4°C for 1 hour, and then co-cultured with CD4^+ T cells or co-injected with B16 melanoma cells for further analysis. For CPI-613 treatment, freshly isolated CD11c^+ cells were pre-treated with DMSO or 10 µM CPI-613 at 37°C for 30 min, and then co-cultured with CD4^+ T cells or co-injected with B16 melanoma cells for further analysis.

**T cell proliferation assay**
CD4+ T cells were isolated from the spleen and labeled with CFSE as previously described (20). CFSE-labeled CD4+ T cells were then co-cultured with isolated CD11c+ cells in 96-well plates pre-coated with anti-CD3 monoclonal antibody (mAb) (2 μg/mL) (145-2C11, cat#553057) and anti-CD28 mAb (5 μg/mL) (37.51, cat#553295) (BD Biosciences) at 37°C, 5% CO2 for 4 days. The ratio of CD11c+ cells /CD4+ T cells was 1:1. Proliferation of CD4+ T cells was evaluated as CFSE dilution by flow cytometry analysis.

**Subcutaneous injection of tumor cells into Lal+/+ mice**

To study the effects of CD11c+ cells on tumor growth, isolated CD11c+ cells (2×10^5) with or without pre-treatment were mixed with B16 melanoma cells (2×10^5), and the cell mixture was injected subcutaneously at the flank region of Lal+/+ recipient mice. The tumor growth was monitored twice a week. The tumor volume (mm^3) was estimated by measuring the maximal length (L) and width (W) of a tumor and calculated using the formula: \( \text{tumor volume} = \frac{L \times W^2}{2} \).

For tumor-bearing mice experiments, wild type (Lal+/+) mice of the FVB/N or C57BL/6 background were injected with 1×10^6 B16 melanoma or LLC cells at flank sites on two sides. Fourteen days later, the mice were sacrificed, and the blood was collected for flow cytometry analysis. To analyze the levels of CD11c+, PD-L1+ or CSF1R+ cells in tumors, tumor tissues from B16 melanoma-injected Lal+/+ or Lal-/ FVB/N mice were harvested, digested for single cell preparation, and stained for flow cytometry analysis.

**Single-cell RNA sequencing and data analysis**
CD11c⁺ cells were sorted from the blood of Lal+/+ and Lal−/− mice as described above. Briefly, the blood from Lal+/+ or Lal−/− mice was removed of RBCs and washed with PBS twice, and then incubated with anti-CD11c microbeads for magnetic bead sorting. Cells obtained after sorting were washed twice with PBS to remove debris and re-suspended in PBS. To obtain equal amount of cell numbers, cells sorted from 10 Lal+/+ mice and 4 Lal−/− mice were pooled together and mixed well. The number and viability of CD11c⁺ cells were 1100 cells/µL and >95%, respectively. Immediately after sorting, CD11c⁺ single cells were run on the 10X Chromium (10X Genomics) and then through library preparation by the Center for Medical Genomics at Indiana University School of Medicine following the recommended protocol for the Chromium Single Cell 3' Reagent Kit. Libraries were run on the NovaSeq S1 for Illumina sequencing.

CellRanger 3.0.2 (http://support.10xgenomics.com/) was utilized to process the raw sequence data generated. CellRanger used bcl2fastq (https://support.illumina.com/) to demultiplex raw base sequence calls generated from the sequencer into sample-specific FASTQ files. The FASTQ files were then aligned to the mouse reference genome mm10 with RNAseq aligner STAR. The aligned reads were traced back to individual cells and the gene expression level of individual genes were quantified based on the number of UMIs (unique molecular indices) detected in each cell. The filtered gene-cell barcode matrices generated by CellRanger were used for further analysis. Cells with unique gene counts over 8000 or having > 10% mitochondrial genes were filtered out. The gene expression was normalized by total expression of the cell, multiplied by a scaling factor 10000, and log2 transformed. Two samples were integrated using FindIntegrationAnchors in Seurat package (54). After scaling the integrated data, the first
13 principle components from principle component analysis (PCA) were used to cluster the cells by a shared nearest neighbor (SNN) modularity optimization based clustering algorithm (55). Clusters were annotated to cell subtypes using SingleR package (56). Visualization was performed with Seurat package. Differential gene expression analysis was analyzed using Wilcoxon Rank Sum test with Seurat package. Trajectory analysis was performed by monocle 2.16.0 (57-59) on ROS response genes (from the Mouse Genome Informatics, or MGI database: http://www.informatics.jax.org/go/term/GO:0000302) using plot_cell_trajectory function after dimensionality reduction with DDRTree algorithm. The accession number is GSE206837.

Pearson correlation analysis of gene expressions of CD11c, PD-L1, CSF1R and IFNγ from the TCGA data base

The Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) (60) (585 samples), Lung Squamous Carcinoma (TCGA-LUSC) (61) (550 samples), and Skin Cutaneous Melanoma (TCGA-SKCM) (472 samples) data were retrieved from UCSC Xena platform (62), which are in whole or partly based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga. Normalized gene expression of CD274, CD11C, CSF1R and IFNG were compared with each other in the tumor samples. Pearson correlation and its p value were calculated. Expression comparisons of gene LIPA (LAL) in Breast Cancer (BRCA), Kidney Chromophobe (KICH), LUAD, LUSC, Pancreatic adenocarcinoma (PAAD), SKCM or Uterine Corpus Endometrial Carcinoma
(UCEC) patients vs. healthy control individuals were also mined from TCGA, including various demographic variable.

**ROS Measurement**

The reactive oxygen species (ROS) level in CD11c$^+$ cells was measured by flow cytometry as previously described (63). White blood cells from $Lat^{+/+}$ and $Lat^{-/-}$ mice were collected as described above and stained with PE-conjugated anti-CD11c antibody and 2 µmol/L 2′, 7′-dichlorofluorescein diacetate (Invitrogen, Carlsbad, CA) at 37°C for 30 min. After PBS wash, the ROS level in CD11c$^+$ cells was analyzed using a LSRII machine.

**Extracellular acidification rate and oxygen consumption rate (Seahorse) assays.**

Extracellular Acidification Rate (ECAR) and Oxygen Consumption Rate (OCR) measurements were performed using a Seahorse Bioscience XF-96 instrument as described previously (64, 65). On the day prior to the experiment, the sensor cartridge was hydrated overnight using the calibration buffer supplied by the manufacturer (Agilent, Santa Clara, CA). On the day of the experiment, CD11c$^+$ cells were freshly isolated as described above, and washed with calibration buffer twice. For ECAR measurement, CD11c$^+$ cells were incubated with glucose-free Seahorse XF base medium supplemented with 2 mM glutamine for 1 h at 37°C in a CO$_2$ free incubator. The injection ports of the sensors were filled with 20~25 µL of treatment or vehicle in buffer. The sensor was then placed into the XF-96 instrument and calibrated. After calibration, the calibration fluid plate was replaced with the cell plate. The measurement cycle consisted of a 2 min mix, 1 min wait, and a 2 min measurement. Four basal rate measurements were followed by
sequential addition of glucose (100 mM), oligomycin (10 µM), and 2-DG (500 mM) prepared in glucose-free Seahorse XF base medium. Each injection was followed by four measurement cycles.

For OCR measurement, CD11c+ cells were incubated with glucose-free Seahorse XF base medium supplemented with 1 mM pyruvate, 2 mM glutamine, and 10 mM glucose for 1 h at 37°C in a CO2 free incubator. The following procedure was similar to ECAR measurement, except that four basal rate measurements were followed by sequential addition of oligomycin (100 µM), carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP, 100 µM), and rotenone/antimycin A (50 µM) prepared in glucose-free Seahorse XF base medium. The consumption rates were calculated from the continuous average slope of the decreased O2 using a compartmentalization model (66). For CD11c+ cells from different genotypes, the rates from 8 wells were used.

LAL activity measurement

The LAL enzymatic activity was determined using 4-methyl-umbelliferyl-oleate (4-MUO) (Sigma, St. Louis, MO) as substrate as described previously (51). Proteins were extracted from HD1A myeloid cells, which have been treated with Lalistat2 or DMSO for 72 hours. Protein concentrations were determined by Pierce™ BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA). Eighteen microgram of protein was added to 0.567 mM substrate solution (0.567 mM 4-MUO, 0.15M sodium acetate/0.01% Tween 80, pH 5.5, 1% (v/v) Triton X-100). Reaction was incubated at 37°C for 30 minutes, and then terminated by adding 100 µL of 0.75 M Tris, pH 8.0. A standard curve was prepared ranging from 0-100 nM 4-methylumbelliferone (4-MU, Sigma). Fluorescence was
measured on a Gemini XPS plate reader (Molecular Devices, San Jose, CA) at 355 nm excitation and 460 nm emission. Data was analyzed using SoftMax program. Assays were linear within the time frame of these assays, and less than 10% of substrate was cleaved. One unit is 1 mmol of 4-MUO cleaved per min under standard assay conditions.

Statistics

Data are expressed as mean ± SD. Differences between two treatment groups were compared by 2-tailed Student's t-test. When more than two groups were compared, one-way ANOVA with post-hoc Newman-Keul’s multiple comparison test was used. When the data were entered into a Grouped table with subcolumns, two-way ANOVA with multiple comparison test was used. A P value less than 0.05 was considered statistically significant. All analyses were performed with GraphPad Prism 8.4.1 (GraphPad, San Diego, CA).

Study approval

All scientific protocols involving the use of animals have been approved by the Institutional Animal Care and Use Committee of Indiana University School of Medicine and followed guidelines established by the Panel on Euthanasia of the American Veterinary Medical Association. Animals were housed under Institutional Animal Care and Use Committee-approved conditions in a secured animal facility at Indiana University School of Medicine. All protocols involving the use of human blood have been approved by the Institutional Biosafety Committee of Indiana University School of Medicine and the written informed consent was received prior to participation.
Author Contributions

T. Z. designed and performed experiments, analyzed and interpreted the data, and wrote the manuscript. J. W. and S. L. analyzed and interpreted the scRNA-seq data. X. D. performed flow cytometry. E. J. maintained mouse colonies and performed genotyping. N. H. provided the human NSCLC blood samples. K. S., and C. S. are responsible for Seahorse analysis. H. D. and C. Y. designed experiments, analyzed and interpreted the data, and wrote the manuscript.
Acknowledgments

This work was supported by NIH Grant CA225108 (C. Y. and H. D.). The human samples from healthy subjects were made possible with support by the Indiana Biobank and the Indiana Clinical and Translational Sciences Institute, funded in part by UL1TR002529 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. The bioinformatics analysis and Flow Cytometry Facility were supported by IU Simon Comprehensive Cancer Center, funded in part by NCI Grant P30CA082709.
References


Figure 1
Figure 1. PD-L1 expression is increased in Lat⁻/⁻ CD11c⁺ cells. A) Percentage of PD-L1⁺ cells in the blood of Lat⁺/+ and Lat⁻/⁻ mice by flow cytometry analysis. B) PD-L1 expression in blood CD11c⁺, MHCII⁺, F4/80⁺, CD11b⁺, Ly6C⁺, Ly6G⁺ cells of Lat⁻/⁻ vs. Lat⁺/+ mice by flow cytometry analysis. C) PD-L1 expression in CD11c⁻ or CD11c⁺ double gating myeloid cells of the Lat⁻/⁻ vs. Lat⁺/+ blood by flow cytometry analysis. D) Percentage of CD11c⁺ cells in the blood of Lat⁺/+ and Lat⁻/⁻ mice by flow cytometry analysis. E) Cytokine expression in Lat⁻/⁻ vs. Lat⁺/+ CD11c⁺ cells by flow cytometry analysis. Data are expressed as mean ± SD; Experiments were independently repeated, n=6 for A-D, n=5 for E. *p<0.05, **p<0.01, unpaired Student’s t test.
Figure 2

A

PBS

CD3+CD28 Abs

CFSE

La\(^{+/+}\)

La\(^{-/-}\)

5.35%

7.46%

78.36%

75.77%

7.46%

75.77%

5.35%

7.46%

78.36%

75.77%

B

% of Divided CD4 T Cells

PBS

CD3+CD28 Abs

La\(^{+/+}\)

La\(^{-/-}\)

**

**

C

IgG

anti-PD-L1

La\(^{+/+}\)

La\(^{-/-}\)

76.71%

75.67%

75.02%

25.47%

24.21%

71.47%

D

Tumor Size (mm\(^3\))

Day

0 7 10 14 17 21

**

**

E

Tumor Size (mm\(^3\))

Day 10

IgG PD-L1 IgG PD-L1

La\(^{+/+}\)

La\(^{-/-}\)

**

**
Figure 2. *Lal*<sup>−/−</sup> CD11c<sup>+</sup> cells suppress T cell proliferation and stimulate tumor cell growth through PD-L1. **A** CFSE-labeled *Lal*<sup>+/+</sup> CD4<sup>+</sup> T cells were stimulated with anti-CD3 mAb plus anti-CD28 mAb for 4 days in the presence or absence of *Lal*<sup>+/+</sup> or *Lal*<sup>−/−</sup> CD11c<sup>+</sup> cells at 1:1 ratio between CD4<sup>+</sup> T cells:CD11c<sup>+</sup> cells. The proliferation of labeled CD4<sup>+</sup> T cells was analyzed by flow cytometry. Peaks represent cell division cycles. PBS was used as a negative control. A representative CFSE dilution by flow cytometry is shown on the left. Statistical analyses of % of divided CD4<sup>+</sup> T cells are on the right. **B** The ratios of CD4<sup>+</sup> T cells:CD11c<sup>+</sup> cells and CD8<sup>+</sup> T cells:CD11c<sup>+</sup> cells in the blood of *Lal*<sup>−/−</sup> vs. *Lal*<sup>+/+</sup> mice were analyzed by flow cytometry analysis. **C** Freshly isolated *Lal*<sup>+/+</sup> or *Lal*<sup>−/−</sup> CD11c<sup>+</sup> cells were pre-treated with IgG or anti-PD-L1 antibody (5 µg/mL), and then co-cultured with CFSE-labeled *Lal*<sup>+/+</sup> CD4<sup>+</sup> T cells (at 1:1 ratio) for T cell proliferation assay as described in (A). **D** B16 melanoma cells (2×10<sup>5</sup>) were mixed with *Lal*<sup>+/+</sup> or *Lal*<sup>−/−</sup> CD11c<sup>+</sup> cells (2×10<sup>5</sup>) and injected subcutaneously at the flank region of *Lal*<sup>+/+</sup> recipient mice. The tumor size was measured at 7-, 10-, 14-, 17- and 21-days post cell injection and determined using the formula: (length × width<sup>2</sup>)/2. **E** *Lal*<sup>+/+</sup> or *Lal*<sup>−/−</sup> CD11c<sup>+</sup> cells were pre-treated with IgG or anti-PD-L1 antibody (5 µg/mL), and then co-injected with B16 melanoma cells into the flank region of *Lal*<sup>+/+</sup> recipient mice. Data are expressed as mean ± SD. Experiments were independently repeated, n=5 for A-C, n=10 for D, and n=16 for E. *p<0.05, **p<0.01, 1-way ANOVA for A and E, unpaired Student’s t test for B and D, 2-way ANOVA for C.
Figure 3

A

B

C

D

E

WT_C158  KO_C158  WT_C0236  KO_C0236

WT_C158  KO_C158  WT_C0236  KO_C0236

WT_C158  KO_C158  WT_C0236  KO_C0236

WT_C158  KO_C158  WT_C0236  KO_C0236
Figure 3. Identification and gene expression of $La$⁻/⁻ vs. $La$⁺/+ CD11c⁺ cell clusters by scRNA-seq. A) tSNE plot of CD11c⁺ cell clusters from $La$⁻/⁻ vs. $La$⁺/+ mice. Each dot represents a single cell colored by cluster assignment. The dotted blue line circles cluster 158, and the dotted red line circles cluster 0236. B) Feature plot of $Cd274$ (PD-L1) expression across cell clusters identified in (A). C) Percentages of cells for expressed genes were increased in cluster 158 and relatively unchanged in cluster 0236 of $La$⁻/⁻ vs. $La$⁺/+ CD11c⁺ cells. The percentage was calculated using the number of expressed cells for the gene divided by the number of cells for this sample. D) Percentages of cells for expressed genes were increased in cluster 158 but decreased in cluster 0236 of $La$⁻/⁻ vs. $La$⁺/+ CD11c⁺ cells. E) Percentages of cells for expressed genes were increased in cluster 0236 but undetectable or increased in cluster 158 of $La$⁻/⁻ vs. $La$⁺/+ CD11c⁺ cells.
Figure 4

A. Glycolysis

B. Citrate cycle

C. MFI of ROS

D. Genes response to ROS

E. Glycolytic Function

F. ATP Production

G. MFI of G6Pase

H. % of CPI-613 Cells

I. % of Divided CPI-613 Cells

J. Day 14

** *
Figure 4. Metabolic reprogramming in Lal−/− CD11c+ cells. Gene expression of A) glycolysis and B) citrate cycle across cell clusters in tSNE plots of CD11c+ cells from Lal−/− vs. Lal+/+ mice. C) Statistical analysis of ROS MFI in Lal−/− vs. Lal+/+ CD11c+ cells by flow cytometry. D) Expression of genes response to ROS across cell clusters in tSNE plots of CD11c+ cells from Lal−/− vs. Lal+/+ mice. E) ECAR of glycolysis and OCR in mitochondrial respiration in Lal−/− vs. Lal+/+ CD11c+ cells. F) ATP production in mitochondrial respiration in Lal−/− vs. Lal+/+ CD11c+ cells. G) MFI of G6PD, PDH, LDH, and GLUD expression in Lal−/− vs. Lal+/+ CD11c+ cells by flow cytometry. H) The percentage of CD11c+ cells in the blood and the percentage of PD-L1+ cells in CD11c+ blood cells after CPI-613 treatment by flow cytometry analysis. I) CPI-613 pre-treated CD11c+ cells were co-cultured with CFSE-labeled Lal+/+ CD4+ T cells for T cell proliferation assay. J) CPI-613 pre-treated CD11c+ cells (2×10^5) were co-injected with B16 melanoma cells (2×10^5) into the flank region of Lal+/+ recipient mice for tumor growth assay. Data are expressed as mean ± SD. Experiments were independently repeated, n=4 for C, G and I, n=6-8 for E-F, n=7 for H, and n=12 for J. *p<0.05, **p<0.01, unpaired Student’s t test for C, F and G, 2-way ANOVA for H and I, 1-way ANOVA for J.
Figure 5. CSF1R expression and function in Lal<sup>i</sup> CD11c<sup>+</sup> cells. A) Csf1r expression across cell clusters in tSNE plots of CD11c<sup>+</sup> cells from Lal<sup>i</sup> vs. Lal<sup>i/+</sup> mice. B) The percentage of CSF1R<sup>+</sup> cells in blood CD11c<sup>+</sup> cells of Lal<sup>i</sup> vs. Lal<sup>i/+</sup> mice by flow cytometry analysis. C) Isolated Lal<sup>i/+</sup> or Lal<sup>i</sup> CD11c<sup>+</sup> cells were pre-treated with IgG or anti-CSF1R antibody (5 µg/mL), and co-cultured with CFSE-labeled Lal<sup>i/+</sup> CD4<sup>+</sup> T cells (at 1:1 ratio). The proliferation of labeled CD4<sup>+</sup> T cells was analyzed by flow cytometry. D) Isolated Lal<sup>i/+</sup> or Lal<sup>i</sup> CD11c<sup>+</sup> cells (2×10<sup>5</sup>) were pre-treated with IgG or anti-CSF1R antibody (5 µg/mL), and co-injected with B16 melanoma cells (2×10<sup>5</sup>) into the flank region of Lal<sup>i/+</sup> recipient mice. The tumor size was measured at 14 days post cell injection. E) The percentage of PD-L1<sup>+</sup> cells in CD11c<sup>+</sup> cells after anti-CSF1R antibody treatment (5 µg/mL) by flow cytometry analysis. F) The percentages of CSF1R<sup>+</sup> cells, PD-L1<sup>+</sup> cells, PD-L1<sup>-</sup>CSF1R<sup>+</sup> cells and IFNγ<sup>+</sup> cells and MFI of IFNγ in blood CD11c<sup>+</sup> cells, and the percentage of blood CD11c<sup>+</sup> cells in Lal<sup>i/+</sup>, Lal<sup>i</sup>, untreated (-DOX), and DOX-treated (+DOX) C-fms-Tg/KO (Tg/KO) mice by flow cytometry analysis. Data are expressed as mean ± SD. Experiments were independently repeated, n=6 for B, n=5 for C and E, n=10 for D, and n=6-7 for F. *p<0.05, **p<0.01, unpaired Student’s t test for B, 2-way ANOVA for C and E, 1-way ANOVA for D and F.
Figure 6

A

LA Activity (U/mg protein)

S 10 50 100 200

Lalistat2 (μM)

B

% CD11c Cells

% PD-1+ Cells

% CSF1R+ Cells

S 10 50 100 200

Lalistat2 (μM)

C

Lalistat2 (μM)

PD-L1

β-actin

D

% CD11c Cells

S L

E

% PD-1+ Cells

% CSF1R+ Cells

S L
Figure 6. Expression of PD-L1 and CSF1R in mouse myeloid cells and human blood CD11c⁺ cells after Lalistat2 treatment. A) The LAL enzymatic activity in HD1A myeloid cells after incubated with 10 µM, 50 µM, 100 µM, 200 µM Lalistat2, or DMSO (S) for 72 h. B) Murine HD1A myeloid cells were incubated with 10 µM, 50 µM, 100 µM, 200 µM Lalistat2, or DMSO (S) for 72 h. The percentages of CD11c⁺, PD-L1⁺, and CSF1R⁺ cells in HD1A myeloid cells were analyzed by flow cytometry. C) Expression of PD-L1 in HD1A myeloid cells after Lalistat2 or DMSO treatment for 72 h by Western blot analysis. Representative blots are shown. D) Human white blood cells from healthy individuals were incubated with 10 µM Lalistat2 (L) or DMSO (S) for 24 h. The percentages of CD11c⁺ cells in the whole white blood cells were analyzed by flow cytometry. E) Percentages of PD-L1⁺ and CSF1R⁺ cells in blood CD11c⁺ cells of healthy individuals treated with Lalistat2 (L) vs. DMSO (S). Data are expressed as mean ± SD; Experiments were independently repeated, n=4 for A and B, n=3 for C, n=6 for D, n=5 for E. *p<0.05, **p<0.01, 1-way ANOVA.
Figure 7. Expression of PD-L1 and CSF1R in CD11c+ cells of tumor bearing mice and NSCLC patients. A) The percentages of CD11c+ blood cells and B) the percentages of PD-L1+ cells in CD11c+ blood cells of B16 melanoma or LLC cell-injected vs. PBS-injected FVB/N or C57BL/6 mice by flow cytometry. C) The percentages of CSF1R+ cells in CD11c+ blood cells of B16 melanoma cells-injected vs. PBS-injected FVB/N mice. D) MFI of PDH expression in CD11c+ blood cells of B16 melanoma cell-injected vs. PBS-injected FVB/N mice. E) CD11c+ blood cells were isolated from B16 melanoma cell-injected or PBS-injected FVB/N mice, and co-cultured with CFSE-labeled Lat+/+ CD4+ T cells (at 1:1 ratio). The proliferation of labeled CD4+ T cells was analyzed by flow cytometry. F-H) Pearson correlation analysis of expressions of CD11C and CD274, CD11C and CSF1R, CD274 and CSF1R, IFNG and CD11C, IFNG and CD274, IFNG and CSF1R in samples of LUAD (F), LUSC (G) and SKCM (H). I) Statistical analysis of percentages of CD11c+, PD-L1+, and CSF1R+ cells in the blood of NSCLC patients vs. healthy individuals. J) Percentages of PD-L1+ and CSF1R+ cells in blood CD11c+ cells of NSCLC patients vs. healthy individuals. K) MFI of PDH expression in blood CD11c+ cells of NSCLC patients vs. healthy individuals. L) Expression of gene LIPA (LAL) in violin plots from BRCA, KICH, LUAD, LUSC, PAAD, SKCM or UCEC patients vs. healthy individuals. M) MFI of LAL in whole blood, CD11c+, PD-L1+, and CSF1R+ cells of NSCLC patients vs. healthy individuals. Data are expressed as mean ± SD; Experiments were independently repeated, n=7-8 for A-D, n=6 for E, n=585 for F, n=550 for G, n=472 for H, n=18-20 for J, n=5-8 for K and M. *p<0.05, **p<0.01, 1-way ANOVA for A and B, unpaired Student’s t test for C-E, I-K and M.